Zeynab Moradian Haft Cheshmeh, M. Asadi-lari, Ali Motlagh, A. Ostovar
Background: Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide, and its incidence has increased in Iran over recent years. Objectives: In this study, we aimed at assessing the completeness of BC pathology reports in the population-based cancer registration system and perform a spatial analysis of the incidence of this cancer in Iran in 2016 to help policymakers develop targeted interventions. Methods: We conducted a retrospective descriptive analysis, using secondary data from the Integrated Cancer Information Management System, and obtained 13789 BC pathology reports from all provinces in Iran in 2016. Pathology data, including tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade were examined for completeness by age group. Results: Pathology reports from 4000 women with BC in 2016 from across all provinces of Iran were selected for this study. The completeness of tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade increased with aging. In addition, the completeness of pathology reports varied across different variables. Accordingly, the tumor grade and pathologic T stage had the highest and lowest completeness rates (100 % versus 27.4%), respectively. Spatial analysis revealed significant high-risk areas for BC incidence, including Isfahan, Markazi, Chaharmahal and Bakhtiari, and Kohgiluyeh and Boyer-Ahmad provinces in central Iran. In contrast, North Khorasan was identified as a low-risk area. Conclusions: Considering the incompleteness of the pathology report in most of the tumor variables in the BC registry, we recognize the gaps to improve pathology data. To ensure effective interventions for BC control, tailored preventive measures are needed, particularly for high-risk areas. Continuous evaluation and data completion, including standard cellular pathology reports, are necessary for accurate BC control in Iran.
背景:乳腺癌(BC)是全世界妇女癌症相关死亡的主要原因，近年来其发病率在伊朗有所增加。目的:在本研究中，我们旨在评估基于人群的癌症登记系统中BC病理报告的完整性，并对2016年伊朗这种癌症的发病率进行空间分析，以帮助政策制定者制定有针对性的干预措施。方法:采用来自癌症综合信息管理系统(Integrated Cancer Information Management System)的二次数据，对2016年伊朗各省13789例BC病理报告进行回顾性描述性分析。病理资料包括肿瘤类型、肿瘤部位、肿瘤大小、病理T分期、病理N分期、肿瘤分级等，按年龄组进行完整性检查。结果:本研究选择了2016年来自伊朗所有省份的4000名BC女性的病理报告。肿瘤类型、肿瘤部位、肿瘤大小、病理T分期、病理N分期、肿瘤分级的完全性随年龄增长而增加。此外，病理报告的完整性在不同变量之间存在差异。因此，肿瘤分级和病理T分期的完成率最高和最低(分别为100%和27.4%)。空间分析显示，BC发病率高的地区包括伊朗中部的伊斯法罕、马卡齐、查哈尔马哈尔和巴赫蒂亚里，以及Kohgiluyeh和Boyer-Ahmad省。相比之下，北呼罗珊被确定为低风险地区。结论:考虑到BC登记中大多数肿瘤变量的病理报告不完整，我们认识到改进病理数据的差距。为了确保有效的BC控制干预措施，需要有针对性的预防措施，特别是在高风险地区。在伊朗，持续的评估和数据的完成，包括标准的细胞病理学报告，对于准确的BC控制是必要的。
{"title":"Examining the Completeness of Breast Cancer Pathology Reports Registered in the Population-based Cancer Registration System and Spatial Analysis of the Incidence of this Cancer in Iran in 2016","authors":"Zeynab Moradian Haft Cheshmeh, M. Asadi-lari, Ali Motlagh, A. Ostovar","doi":"10.5812/ijcm-137092","DOIUrl":"https://doi.org/10.5812/ijcm-137092","url":null,"abstract":"Background: Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide, and its incidence has increased in Iran over recent years. Objectives: In this study, we aimed at assessing the completeness of BC pathology reports in the population-based cancer registration system and perform a spatial analysis of the incidence of this cancer in Iran in 2016 to help policymakers develop targeted interventions. Methods: We conducted a retrospective descriptive analysis, using secondary data from the Integrated Cancer Information Management System, and obtained 13789 BC pathology reports from all provinces in Iran in 2016. Pathology data, including tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade were examined for completeness by age group. Results: Pathology reports from 4000 women with BC in 2016 from across all provinces of Iran were selected for this study. The completeness of tumor type, tumor site, tumor size, pathologic T stage, pathologic N stage, and tumor grade increased with aging. In addition, the completeness of pathology reports varied across different variables. Accordingly, the tumor grade and pathologic T stage had the highest and lowest completeness rates (100 % versus 27.4%), respectively. Spatial analysis revealed significant high-risk areas for BC incidence, including Isfahan, Markazi, Chaharmahal and Bakhtiari, and Kohgiluyeh and Boyer-Ahmad provinces in central Iran. In contrast, North Khorasan was identified as a low-risk area. Conclusions: Considering the incompleteness of the pathology report in most of the tumor variables in the BC registry, we recognize the gaps to improve pathology data. To ensure effective interventions for BC control, tailored preventive measures are needed, particularly for high-risk areas. Continuous evaluation and data completion, including standard cellular pathology reports, are necessary for accurate BC control in Iran.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75894405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seyed Amir Miratashi Yazdi, Saeede Miri, Atie Moghtadaie, E. Nazar
Background: Due to the close association of CD31 marker positivity and tumor microvessel density, the relationship between this marker and the pathophysiological behavior of the tumor, such as the ability to invade the surrounding tissues and organ damage, is also quite probable. Objectives: We aimed at evaluating the association of CD31 expression with the likelihood of microvascular invasion and other abnormal histopathological findings in patients with colorectal cancer. Methods: In our cross-sectional study, the pathology numbers of 50 samples that were diagnosed with colorectal cancer in their pathology report during 2021 and 2022 were identified by searching our hospital information system. Immunohistochemical staining (IHC) using CD31 monoclonal antibody was performed for assessing CD31 positivity. Results: CD31 positivity was found in 34.0% of cases, 35.5% in colon masses, and 31.6% in rectal masses. The patients with positive CD31 had significantly higher tumor grades (P < 0.045). The prevalence rate of vascular invasion was significantly higher in patients with positive CD31 compared to those with negative CD31 states (47.1% versus 12.1%, P = 0.006). Also, the rate of lymph node involvement in the groups with positive and negative CD31 was 58.8% and 24.2%, respectively, indicating a significant difference (P = 0.016). In multivariable logistic regression models, CD31 positivity was shown to be associated with the risk for vascular invasion (OR = 6.211, P = 0.020) and lymph node involvement (OR = 6.535, P = 0.011). Conclusions: CD31 positivity in patients with colorectal cancer can effectively predict invasive behavior of the tumor including vascular invasion, lymph node involvement, and high tumor grades.
背景:由于CD31标志物阳性与肿瘤微血管密度密切相关，因此该标志物与肿瘤的病理生理行为，如侵袭周围组织和器官损伤的能力之间的关系也很有可能。目的:我们旨在评估CD31表达与结直肠癌患者微血管侵袭可能性和其他异常组织病理学结果的关系。方法:在横断面研究中，通过检索我院信息系统，确定2021年至2022年期间50例在病理报告中诊断为结直肠癌的样本的病理编号。CD31单克隆抗体免疫组化染色(IHC)检测CD31阳性。结果:CD31阳性率为34.0%，结肠肿块阳性率为35.5%，直肠肿块阳性率为31.6%。CD31阳性患者肿瘤分级明显增高(P < 0.045)。CD31阳性患者血管浸润率明显高于CD31阴性患者(47.1% vs 12.1%， P = 0.006)。CD31阳性和阴性组的淋巴结受累率分别为58.8%和24.2%，差异有统计学意义(P = 0.016)。在多变量logistic回归模型中，CD31阳性与血管侵犯(OR = 6.211, P = 0.020)和淋巴结受累(OR = 6.535, P = 0.011)的风险相关。结论:结直肠癌患者CD31阳性可有效预测肿瘤的侵袭行为，包括血管侵犯、淋巴结累及及肿瘤的高分级。
{"title":"CD31 Positivity and Prediction of Tumor Invasive Behavior in Colorectal Cancer","authors":"Seyed Amir Miratashi Yazdi, Saeede Miri, Atie Moghtadaie, E. Nazar","doi":"10.5812/ijcm-136132","DOIUrl":"https://doi.org/10.5812/ijcm-136132","url":null,"abstract":"Background: Due to the close association of CD31 marker positivity and tumor microvessel density, the relationship between this marker and the pathophysiological behavior of the tumor, such as the ability to invade the surrounding tissues and organ damage, is also quite probable. Objectives: We aimed at evaluating the association of CD31 expression with the likelihood of microvascular invasion and other abnormal histopathological findings in patients with colorectal cancer. Methods: In our cross-sectional study, the pathology numbers of 50 samples that were diagnosed with colorectal cancer in their pathology report during 2021 and 2022 were identified by searching our hospital information system. Immunohistochemical staining (IHC) using CD31 monoclonal antibody was performed for assessing CD31 positivity. Results: CD31 positivity was found in 34.0% of cases, 35.5% in colon masses, and 31.6% in rectal masses. The patients with positive CD31 had significantly higher tumor grades (P < 0.045). The prevalence rate of vascular invasion was significantly higher in patients with positive CD31 compared to those with negative CD31 states (47.1% versus 12.1%, P = 0.006). Also, the rate of lymph node involvement in the groups with positive and negative CD31 was 58.8% and 24.2%, respectively, indicating a significant difference (P = 0.016). In multivariable logistic regression models, CD31 positivity was shown to be associated with the risk for vascular invasion (OR = 6.211, P = 0.020) and lymph node involvement (OR = 6.535, P = 0.011). Conclusions: CD31 positivity in patients with colorectal cancer can effectively predict invasive behavior of the tumor including vascular invasion, lymph node involvement, and high tumor grades.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82747817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Moslem Arian, M. Khanjani, A. Ebadi, S. Younesi, M. Azkhosh, S. Hosseinzadeh, A. Nikoofar
Context: Existential guilt is an important concept in cancer patients. However, the literature shows that the components of this concept are not well defined and specified. Hence, this study aimed at enhancing understanding of the characteristics of existential guilt and its differentiation from other similar concepts in the field of cancer. Evidence Acquisition: Focusing on cancer patients, Walker & Avant's approach was followed to clarify and analyze the concept of existential guilt. So, Web of Sciences (ISI), PubMed, ProQuest, Scopus, PsycINFO databases, and Google Scholar were searched, using 'existential guilt', 'guilt', and 'cancer' keywords to identify relevant studies with no time limitation. After screening and evaluation, 58 articles were identified, of which 26 were analyzed. Results: Initially, definitions, characteristics, antecedents, and consequences of the existential guilt concept were introduced. Then, a case model was explained to create a more clarified understanding of the concept and, eventually, some implications for the approach to cancer patients were proposed. Conclusions: The existence of different definitions and separate research pathways about the concept of existential guilt may indicate a sense of scatteredness. However, as shown in this study, one can come to a widely accepted understanding as well as a differential understanding of this concept; this clarification can, in turn, result in efficient and comprehensive psychological attention to cancer patients. Indeed, this concept analysis can pave the way for clinical interventions, operationalization, and research on this topic and population
背景:存在性内疚是癌症患者的一个重要概念。然而，文献表明，这一概念的组成部分没有很好地定义和规定。因此，本研究旨在加强对存在性内疚的特征及其与癌症领域其他类似概念的区别的理解。证据获取:以癌症患者为研究对象，采用Walker & Avant的方法来厘清和分析存在性罪恶感的概念。因此，我们搜索了Web of Sciences (ISI)、PubMed、ProQuest、Scopus、PsycINFO数据库和Google Scholar，使用“存在性内疚”、“内疚”和“癌症”关键词来识别相关研究，没有时间限制。经筛选评价，共鉴定出58篇，其中26篇进行分析。结果:首先介绍了存在性内疚概念的定义、特征、前因和后果。然后，解释了一个案例模型，以更清楚地理解这一概念，并最终提出了对癌症患者方法的一些启示。结论:存在性内疚感的不同定义和研究路径的存在可能表明存在性内疚感的分散感。然而，正如本研究所示，人们对这一概念可以有广泛接受的理解，也可以有不同的理解;这种澄清反过来又能给癌症患者带来有效和全面的心理关注。事实上，这一概念分析可以为临床干预、操作化以及对这一主题和人口的研究铺平道路
{"title":"Existential Guilt in Cancer Patients: A Concept Analysis","authors":"Moslem Arian, M. Khanjani, A. Ebadi, S. Younesi, M. Azkhosh, S. Hosseinzadeh, A. Nikoofar","doi":"10.5812/ijcm-136219","DOIUrl":"https://doi.org/10.5812/ijcm-136219","url":null,"abstract":"Context: Existential guilt is an important concept in cancer patients. However, the literature shows that the components of this concept are not well defined and specified. Hence, this study aimed at enhancing understanding of the characteristics of existential guilt and its differentiation from other similar concepts in the field of cancer. Evidence Acquisition: Focusing on cancer patients, Walker & Avant's approach was followed to clarify and analyze the concept of existential guilt. So, Web of Sciences (ISI), PubMed, ProQuest, Scopus, PsycINFO databases, and Google Scholar were searched, using 'existential guilt', 'guilt', and 'cancer' keywords to identify relevant studies with no time limitation. After screening and evaluation, 58 articles were identified, of which 26 were analyzed. Results: Initially, definitions, characteristics, antecedents, and consequences of the existential guilt concept were introduced. Then, a case model was explained to create a more clarified understanding of the concept and, eventually, some implications for the approach to cancer patients were proposed. Conclusions: The existence of different definitions and separate research pathways about the concept of existential guilt may indicate a sense of scatteredness. However, as shown in this study, one can come to a widely accepted understanding as well as a differential understanding of this concept; this clarification can, in turn, result in efficient and comprehensive psychological attention to cancer patients. Indeed, this concept analysis can pave the way for clinical interventions, operationalization, and research on this topic and population","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84055919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Sobhani, E. Salehifar, Parisa Moradimajd, E. Zaboli, M. Mohsenzadegan, H. Samaee
Context: One of the most common cancers in men is prostate cancer, which can lead to death. Immune checkpoint inhibitors (ICIs) are drugs that have been proposed in recent years as proposed treatments for prostate cancer. Objectives: The aim of this study was to review the efficacy and tolerability of ICIs in these patients. Data Sources: From January 1, 1990, to January 1, 2022, using the keywords in checkpoint inhibitors, prostate cancer, efficacy, and tolerability, systematically reviewed databases such as PubMed, ClinicalTrial.gov, Web of Science, Scopus, Cochrane Library, ScienceDirect and Google Scholar based on the protocol registered in Prospero were identified as CRD42021252562. Results: Out of 690 studies found, 43 studies were reviewed for evaluation in terms of inclusion criteria, and finally 6 studies were included in the design. In the analysis of selected studies, 1 800 patients were studied, and the range of sample size was from 23 to 799. According to the results of the meta-analysis, there was no significant difference in death risk compared to ICI + radiotherapy with radiotherapy + placebo (HR: 0.96, 95% CI: 0.74, 1.23, P = 0.74). Combined results from 2 clinical trials demonstrated that the risk of death in the radiotherapy + ICI group was less than in the group just treated with radiotherapy (HR: 0.69, 95% CI: 0.61, 0.77, (P < 0.001), 0.77, P < 0.001). To evaluate tolerability, the results showed a non-significant difference between the groups considering the overall prevalence of treatment-related side effects (RR: 1.59, 95% CI: 0.75, 3.39, I2 = 98%). Conclusions: The present meta-analysis showed that the use of safety checkpoint inhibitors has been associated with improved survival without progression, but their effect on increasing overall survival has not been confirmed.
{"title":"Systematic Review and Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors in the Treatment of Prostate Cancer","authors":"M. Sobhani, E. Salehifar, Parisa Moradimajd, E. Zaboli, M. Mohsenzadegan, H. Samaee","doi":"10.5812/ijcm-135393","DOIUrl":"https://doi.org/10.5812/ijcm-135393","url":null,"abstract":"Context: One of the most common cancers in men is prostate cancer, which can lead to death. Immune checkpoint inhibitors (ICIs) are drugs that have been proposed in recent years as proposed treatments for prostate cancer. Objectives: The aim of this study was to review the efficacy and tolerability of ICIs in these patients. Data Sources: From January 1, 1990, to January 1, 2022, using the keywords in checkpoint inhibitors, prostate cancer, efficacy, and tolerability, systematically reviewed databases such as PubMed, ClinicalTrial.gov, Web of Science, Scopus, Cochrane Library, ScienceDirect and Google Scholar based on the protocol registered in Prospero were identified as CRD42021252562. Results: Out of 690 studies found, 43 studies were reviewed for evaluation in terms of inclusion criteria, and finally 6 studies were included in the design. In the analysis of selected studies, 1 800 patients were studied, and the range of sample size was from 23 to 799. According to the results of the meta-analysis, there was no significant difference in death risk compared to ICI + radiotherapy with radiotherapy + placebo (HR: 0.96, 95% CI: 0.74, 1.23, P = 0.74). Combined results from 2 clinical trials demonstrated that the risk of death in the radiotherapy + ICI group was less than in the group just treated with radiotherapy (HR: 0.69, 95% CI: 0.61, 0.77, (P < 0.001), 0.77, P < 0.001). To evaluate tolerability, the results showed a non-significant difference between the groups considering the overall prevalence of treatment-related side effects (RR: 1.59, 95% CI: 0.75, 3.39, I2 = 98%). Conclusions: The present meta-analysis showed that the use of safety checkpoint inhibitors has been associated with improved survival without progression, but their effect on increasing overall survival has not been confirmed.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87709140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Arjmand, M. Rezaei-Tavirani, Maryam Hamzeloo-Moghadam3, Z. Razzaghi, M. Rezaei-Tavirani
Background: The radiation resistance process is a major problem in radiotherapy. Proteomics is a useful method to determine the molecular mechanism of biological and medical events. Protein-protein interaction (PPI) network is a suitable method for proteomics data interpretation. Objectives: Assessment of proteomics data about the radiation resistance process in human cell lines via PPI network analysis is the aim of this study. Methods: Proteomic data were extracted from literature and the differentially expressed proteins (DEPs) were included in the PPI network via the STRING database by Cytoscape software. The network was analyzed and the central nodes were introduced. The central nodes were assessed via action map analysis and gene ontology enrichment. Results: Among the 251 queried DEPs, 171 individuals were included in the PPI network. EGFR, FN1, CD44, PTGS2, NFKBIA, KEAP1, CTSD, PHGDH, and NT5E were introduced as the critical DEPs. Eight groups of biological terms were attributed to the introduced critical DEPs. EGFR, FN1, CD44, and PTGS2 were discriminated among the critical DEPs as the key dysregulated proteins. Conclusions: The results indicate that EGFR, FN1, CD44, and PTGS2 are the four essential proteins that are involved in radiation resistance in the radioresistant cells.
{"title":"Molecular Analysis of Radiation Resistance Process in Radioresistant Oesophageal Adenocarcinoma Cells","authors":"B. Arjmand, M. Rezaei-Tavirani, Maryam Hamzeloo-Moghadam3, Z. Razzaghi, M. Rezaei-Tavirani","doi":"10.5812/ijcm-134017","DOIUrl":"https://doi.org/10.5812/ijcm-134017","url":null,"abstract":"Background: The radiation resistance process is a major problem in radiotherapy. Proteomics is a useful method to determine the molecular mechanism of biological and medical events. Protein-protein interaction (PPI) network is a suitable method for proteomics data interpretation. Objectives: Assessment of proteomics data about the radiation resistance process in human cell lines via PPI network analysis is the aim of this study. Methods: Proteomic data were extracted from literature and the differentially expressed proteins (DEPs) were included in the PPI network via the STRING database by Cytoscape software. The network was analyzed and the central nodes were introduced. The central nodes were assessed via action map analysis and gene ontology enrichment. Results: Among the 251 queried DEPs, 171 individuals were included in the PPI network. EGFR, FN1, CD44, PTGS2, NFKBIA, KEAP1, CTSD, PHGDH, and NT5E were introduced as the critical DEPs. Eight groups of biological terms were attributed to the introduced critical DEPs. EGFR, FN1, CD44, and PTGS2 were discriminated among the critical DEPs as the key dysregulated proteins. Conclusions: The results indicate that EGFR, FN1, CD44, and PTGS2 are the four essential proteins that are involved in radiation resistance in the radioresistant cells.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78684334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Nowroozi, E. Amini, Ehsan Mosa Farkhani, Ali Nowroozi, M. Ayati, Seyed Ali Momeni, Sepideh Mirzaei, K. Hushmandi, L. Sharifi, S. Bokaie
Background: Bladder cancer is one of the most common cancers worldwide and also in Iran. Understanding of bladder cancer epidemiology is of great value for policymakers and assists in the prevention and early detection of the disease. Objectives: The aim of the present study was to report national and subnational incidence trends of bladder cancer in Iran between 2003 and 2015. Methods: This study investigated the age-standardized incidence rates (ASIRs) per annum of bladder cancer from 2003 to 2015 in Iran using the data from the cancer registration system of the Ministry of Health and Medical Education of Iran. The crude incidence rates were calculated by dividing incident cases by the country and province population, which were provided by the Statistic Center of Iran. Age standardization was performed using the WHO standard population, and ASIRs were compared by age, sex, and province. Results: The ASIR of bladder cancer increased from 8.35 in 2003 to 13.57 in 2015 in men. The ASIR of bladder cancer also showed a mild increase in females, 2.12 in 2003 versus 2.86 in 2015. The province of Yazd had the highest rate of bladder cancer in men, and West Azerbaijan had the highest rate for women (15.13 and 7.79 per 100,000), while Sistan va Baluchestan and Ilam had the lowest ASIRs for men and women (3.01 and 0.96 per 100,000, respectively). Conclusions: The increasing trend of bladder cancer incidence in Iran, despite the clear decreasing global trend accompanying to ongoing aging of the population highlights the diseases as a potential health problem in the upcoming years in Iran. Therefore, it is necessary for health organizations to implement effective research and control programs in the country to prevent further increases in disease burden.
{"title":"National and Subnational Incidence Trend of Bladder Cancer in Iran: Report of a 12-Year Period","authors":"M. Nowroozi, E. Amini, Ehsan Mosa Farkhani, Ali Nowroozi, M. Ayati, Seyed Ali Momeni, Sepideh Mirzaei, K. Hushmandi, L. Sharifi, S. Bokaie","doi":"10.5812/ijcm-127005","DOIUrl":"https://doi.org/10.5812/ijcm-127005","url":null,"abstract":"Background: Bladder cancer is one of the most common cancers worldwide and also in Iran. Understanding of bladder cancer epidemiology is of great value for policymakers and assists in the prevention and early detection of the disease. Objectives: The aim of the present study was to report national and subnational incidence trends of bladder cancer in Iran between 2003 and 2015. Methods: This study investigated the age-standardized incidence rates (ASIRs) per annum of bladder cancer from 2003 to 2015 in Iran using the data from the cancer registration system of the Ministry of Health and Medical Education of Iran. The crude incidence rates were calculated by dividing incident cases by the country and province population, which were provided by the Statistic Center of Iran. Age standardization was performed using the WHO standard population, and ASIRs were compared by age, sex, and province. Results: The ASIR of bladder cancer increased from 8.35 in 2003 to 13.57 in 2015 in men. The ASIR of bladder cancer also showed a mild increase in females, 2.12 in 2003 versus 2.86 in 2015. The province of Yazd had the highest rate of bladder cancer in men, and West Azerbaijan had the highest rate for women (15.13 and 7.79 per 100,000), while Sistan va Baluchestan and Ilam had the lowest ASIRs for men and women (3.01 and 0.96 per 100,000, respectively). Conclusions: The increasing trend of bladder cancer incidence in Iran, despite the clear decreasing global trend accompanying to ongoing aging of the population highlights the diseases as a potential health problem in the upcoming years in Iran. Therefore, it is necessary for health organizations to implement effective research and control programs in the country to prevent further increases in disease burden.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83995151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Despite the high prevalence of head and neck cancers in Iran, no studies have been conducted to investigate the relationship between vitamin D levels and these cancers. Many Iranians suffer from vitamin D deficiency, which underscores the importance of conducting these studies in Iran. Objectives: This study aims at investigating the relationship between vitamin D levels and laryngeal cancer. Methods: This 1: 1 matched case-control study included 216 patients in Mashhad, Iran, who had not consumed vitamin D supplements for 3-months before study onset. Participants were grouped in 2 categories; the case group, which consisted of patients with laryngeal cancer whose squamous cell carcinoma was confirmed pathologically for the first time (new cases), and the control group, which consisted of individuals who did not have any cancer at the time of the study, confirmed by indirect laryngoscopy, and were identical to the patient group in terms of other risk factors for laryngeal cancer (smoking and alcohol abuse). First, the relevant checklist (including age, occupation, consumption of tobacco, alcohol use, etc., history of contact with mustard gas, wood, stone, metal, and cement industry, as well as history of reflux in the individual and cancer in relatives) was completed for all case and control group members. After taking blood samples, they were evaluated for serum levels of vitamin D3. Data were analyzed using chi-square, Mann-Whitney U or independent sample t-tests. Logistic regression was also used to determine the relation between vitamin D level and laryngeal cancer. Results: Mean age, sex and risk factors of laryngeal cancer were not significantly different between the two groups. Vitamin D level was significantly lower in patients with laryngeal cancer compared to control group (16.02 ± 3.62 ng/mL vs 25.19 ± 3.40 (P < 0.001)). Logistic regression analysis showed that vitamin D level is independently related to laryngeal cancer and has a protective effect on this neoplasm (OR = 0.54, 95%CI: 0.46 - 0.63, P < 0.001). Conclusions: A lower vitamin D level may be related to laryngeal cancer. However, the role of vitamin D deficiency as a risk factor for head and neck cancers and whether the treatment of this condition could prevent the incidence of such cancers is a matter of future investigations.
背景:尽管伊朗头颈癌发病率很高，但没有研究调查维生素D水平与这些癌症之间的关系。许多伊朗人患有维生素D缺乏症，这强调了在伊朗进行这些研究的重要性。目的:探讨维生素D水平与喉癌的关系。方法:这项1:1匹配的病例对照研究纳入了伊朗马什哈德的216例患者，他们在研究开始前3个月没有服用维生素D补充剂。参与者分为两类;病例组包括首次病理确诊为喉癌鳞状细胞癌的喉癌患者(新病例)，对照组包括在研究时没有任何癌症的个体，通过间接喉镜检查确诊，在喉癌的其他危险因素(吸烟和酗酒)方面与患者组相同。首先，完成所有病例组和对照组成员的相关核对表(包括年龄、职业、吸烟、饮酒等，芥子气、木材、石头、金属和水泥工业接触史，以及个人反流史和亲属癌症史)。在采集了血液样本后，对他们的血清维生素D3水平进行了评估。数据分析采用卡方检验、Mann-Whitney U检验或独立样本t检验。采用Logistic回归法确定维生素D水平与喉癌的关系。结果:两组患者喉癌的平均年龄、性别及危险因素无显著差异。喉癌患者的维生素D水平明显低于对照组(16.02±3.62 ng/mL vs 25.19±3.40 ng/mL, P < 0.001)。Logistic回归分析显示，维生素D水平与喉癌独立相关，对喉癌有保护作用(OR = 0.54, 95%CI: 0.46 ~ 0.63, P < 0.001)。结论:低维生素D水平可能与喉癌有关。然而，维生素D缺乏作为头颈癌风险因素的作用，以及这种情况的治疗是否能预防此类癌症的发生，还有待于未来的研究。
{"title":"The Relationship Between Vitamin D Deficiency and Laryngeal Cancer in Iran: A Case-control Study in Mashhad","authors":"Ehsan Khadivi, Negar Moghaddas, Hamidreza Rasti Boroujeni, Bashir Rasoulian, Mohammadreza Afzalzadeh, Maryam Emadzadeh, Fatemeh Forouzanfar","doi":"10.5812/ijcm-135578","DOIUrl":"https://doi.org/10.5812/ijcm-135578","url":null,"abstract":"Background: Despite the high prevalence of head and neck cancers in Iran, no studies have been conducted to investigate the relationship between vitamin D levels and these cancers. Many Iranians suffer from vitamin D deficiency, which underscores the importance of conducting these studies in Iran. Objectives: This study aims at investigating the relationship between vitamin D levels and laryngeal cancer. Methods: This 1: 1 matched case-control study included 216 patients in Mashhad, Iran, who had not consumed vitamin D supplements for 3-months before study onset. Participants were grouped in 2 categories; the case group, which consisted of patients with laryngeal cancer whose squamous cell carcinoma was confirmed pathologically for the first time (new cases), and the control group, which consisted of individuals who did not have any cancer at the time of the study, confirmed by indirect laryngoscopy, and were identical to the patient group in terms of other risk factors for laryngeal cancer (smoking and alcohol abuse). First, the relevant checklist (including age, occupation, consumption of tobacco, alcohol use, etc., history of contact with mustard gas, wood, stone, metal, and cement industry, as well as history of reflux in the individual and cancer in relatives) was completed for all case and control group members. After taking blood samples, they were evaluated for serum levels of vitamin D3. Data were analyzed using chi-square, Mann-Whitney U or independent sample t-tests. Logistic regression was also used to determine the relation between vitamin D level and laryngeal cancer. Results: Mean age, sex and risk factors of laryngeal cancer were not significantly different between the two groups. Vitamin D level was significantly lower in patients with laryngeal cancer compared to control group (16.02 ± 3.62 ng/mL vs 25.19 ± 3.40 (P < 0.001)). Logistic regression analysis showed that vitamin D level is independently related to laryngeal cancer and has a protective effect on this neoplasm (OR = 0.54, 95%CI: 0.46 - 0.63, P < 0.001). Conclusions: A lower vitamin D level may be related to laryngeal cancer. However, the role of vitamin D deficiency as a risk factor for head and neck cancers and whether the treatment of this condition could prevent the incidence of such cancers is a matter of future investigations.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90142799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Tayebi, Fatemeh Karkhaneh, Ghazaleh Donyadideh, Faranak Olamaeian, Mohammad Javad Ashoori, Mansour Bahahrdoust, A. Tizmaghz
Background: Colorectal cancer (CC) is one of the most important causes of death due to cancer in the world. The association of blood groups with CC in many races has been reported in previous studies. So far, no study has evaluated the relationship between blood group type, tumor location, and polyp type. Objectives: This study aimed at evaluating the association of the ABO blood group and CC, tumor location, and polyp type. Methods: In this case-control study, 802 subjects (401 cases and 401 controls), who underwent surgery at our medical centers between 2014 and 2021, were included. The case group was selected from the hospital records of patients with CC, and the controls were selected from non-cancer patients who were admitted to the same centers for reasons other than cancer. Patients’ demographic characteristics and clinical and pathology findings were extracted from the medical profile, and blood group information was extracted from the blood bank. Multivariate logistic regression analysis was used for the predictive variables of CC. Results: The risk of CC in patients with blood type A was significantly higher than non-A. While the risk of developing CC in patients with blood type O was significantly lower than non-O O. The risk of developing neoplastic polyps was significantly higher in patients with blood type A compared to non-A. The results of multivariate analysis showed that ABO blood type A (OR Adju: 1.66) and O (OR Adju: 0.78) and neoplastic polyp type (OR Adju: 1.36,) were associated with CC. Conclusions: The results of this study showed that ABO blood group type was significantly related to CC and polyp type.
{"title":"Evaluation of the Association of Blood Group Type with Tumor Location, Polyp Type, and Colorectal Cancer Risk: A Case-control Study","authors":"A. Tayebi, Fatemeh Karkhaneh, Ghazaleh Donyadideh, Faranak Olamaeian, Mohammad Javad Ashoori, Mansour Bahahrdoust, A. Tizmaghz","doi":"10.5812/ijcm-136225","DOIUrl":"https://doi.org/10.5812/ijcm-136225","url":null,"abstract":"Background: Colorectal cancer (CC) is one of the most important causes of death due to cancer in the world. The association of blood groups with CC in many races has been reported in previous studies. So far, no study has evaluated the relationship between blood group type, tumor location, and polyp type. Objectives: This study aimed at evaluating the association of the ABO blood group and CC, tumor location, and polyp type. Methods: In this case-control study, 802 subjects (401 cases and 401 controls), who underwent surgery at our medical centers between 2014 and 2021, were included. The case group was selected from the hospital records of patients with CC, and the controls were selected from non-cancer patients who were admitted to the same centers for reasons other than cancer. Patients’ demographic characteristics and clinical and pathology findings were extracted from the medical profile, and blood group information was extracted from the blood bank. Multivariate logistic regression analysis was used for the predictive variables of CC. Results: The risk of CC in patients with blood type A was significantly higher than non-A. While the risk of developing CC in patients with blood type O was significantly lower than non-O O. The risk of developing neoplastic polyps was significantly higher in patients with blood type A compared to non-A. The results of multivariate analysis showed that ABO blood type A (OR Adju: 1.66) and O (OR Adju: 0.78) and neoplastic polyp type (OR Adju: 1.36,) were associated with CC. Conclusions: The results of this study showed that ABO blood group type was significantly related to CC and polyp type.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85490655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Context: Primary brain tumor (PBT) causes poor prognosis and significant complications, which include movement problems such as balance disorders, failed return to work, and daily life activities. Objectives: The aim of the present study is to estimate the prevalence of PBT in Iran, using a meta-analysis method. Methods: This meta-analysis study was conducted in Iran in 2023 and articles published until the beginning of 2023 were included in the study, using the English keywords of brain cancer, brain tumor, tumor prevalence, prevalence, cancer, nervous system cancer, and their Persian equivalents. Data analysis was carried out, using CMA software. Results: After the initial search, 890 articles on BT were found, and 21 eligible articles were included in the meta-analysis. Also, the prevalence of brain cancer is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women. Conclusions: According to the result, the BT incidence rate is 4% for males and 2.9% for females. Therefore, it is necessary to take necessary preventive measures in this regard.
{"title":"Incidence Trend of Brain Tumors in Iran: A Systematic Review and Meta-analysis","authors":"Sohrab Sadeghi, Hassan Reza Mohammadi","doi":"10.5812/ijcm-136310","DOIUrl":"https://doi.org/10.5812/ijcm-136310","url":null,"abstract":"Context: Primary brain tumor (PBT) causes poor prognosis and significant complications, which include movement problems such as balance disorders, failed return to work, and daily life activities. Objectives: The aim of the present study is to estimate the prevalence of PBT in Iran, using a meta-analysis method. Methods: This meta-analysis study was conducted in Iran in 2023 and articles published until the beginning of 2023 were included in the study, using the English keywords of brain cancer, brain tumor, tumor prevalence, prevalence, cancer, nervous system cancer, and their Persian equivalents. Data analysis was carried out, using CMA software. Results: After the initial search, 890 articles on BT were found, and 21 eligible articles were included in the meta-analysis. Also, the prevalence of brain cancer is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women. Conclusions: According to the result, the BT incidence rate is 4% for males and 2.9% for females. Therefore, it is necessary to take necessary preventive measures in this regard.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86188232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam Kalantari Khandani, S. Azghandi, Z. Siavashpour, A. Rakhsha, Amir Shahram Yousefi Kashi, Arian Yousefi Kashi
Background: The aim of this study was to evaluate and analyze disease-free survival (DFS) and overall survival (OS) after intensity-modulated radiotherapy (IMRT) for Iranian patients with nasopharyngeal carcinoma (NC). Methods: In this historical cohort study, 65 non-metastatic patients treated for NC with IMRT were selected and reviewed at the Shohadai-e-Tajrish Hospital between October 2017 and October 2019. Chemotherapy was given either as induction, concurrent, or adjuvant therapy in all cases. Three years of DFS and OS were calculated according to Kaplan-Meier and compared with the Pearson Correlation Test. Results: The mean age of patients was 43.38 years. The three-year DFS and OS rates were 95.72%, 92.32%, 72.73%, 73.26%, and 100%, 84.61%, 90.90%, and 79.41% in stage I, II, III, and IV patients, respectively (P = 0.119, P = 0.155). The total three-year DFS rate and the total three-year OS rate were 76.47% and 84.60% in all cases. Based on the Pearson Correlation Test, it was a significant correlation between the duration of IMRT time and three-year DFS (correlation=0.138, P = 0.017) and the number of concurrent cycles of chemotherapy with IMRT (correlation=0.375, P = 0.002). It was not a significant correlation between total time duration, MRI response, induction chemotherapy, age, sex, and the three-year DFS. There was a significant correlation between total time duration and three-year OS (correlation=0.263, P = 0.040) and the number of concurrent cycles of chemotherapy with IMRT and three-year OS (correlation=0.334, P = 0.007). It was not a significant correlation between the duration of IMRT time, MRI response, induction chemotherapy, age, sex, and the three-year OS. Conclusions: Our findings showed that IMRT with concurrent chemo-radiotherapy has the three-year DFS and OS, which were comparable with the other published results. We emphasize the number of concurrent cycles of chemotherapy with IMRT, which have an important role in both three-year DFS and OS. The duration of IMRT time has also an important role in the three-year DFS but not in the three-year OS. A longer follow-up for the patients to evaluate 10-year DFS and OS is recommended.
{"title":"Evaluation of Three-year Overall and Disease-free Survival in Iranian Patients with Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy (IMRT): A Historical Cohort Single Center Study","authors":"Maryam Kalantari Khandani, S. Azghandi, Z. Siavashpour, A. Rakhsha, Amir Shahram Yousefi Kashi, Arian Yousefi Kashi","doi":"10.5812/ijcm-136257","DOIUrl":"https://doi.org/10.5812/ijcm-136257","url":null,"abstract":"Background: The aim of this study was to evaluate and analyze disease-free survival (DFS) and overall survival (OS) after intensity-modulated radiotherapy (IMRT) for Iranian patients with nasopharyngeal carcinoma (NC). Methods: In this historical cohort study, 65 non-metastatic patients treated for NC with IMRT were selected and reviewed at the Shohadai-e-Tajrish Hospital between October 2017 and October 2019. Chemotherapy was given either as induction, concurrent, or adjuvant therapy in all cases. Three years of DFS and OS were calculated according to Kaplan-Meier and compared with the Pearson Correlation Test. Results: The mean age of patients was 43.38 years. The three-year DFS and OS rates were 95.72%, 92.32%, 72.73%, 73.26%, and 100%, 84.61%, 90.90%, and 79.41% in stage I, II, III, and IV patients, respectively (P = 0.119, P = 0.155). The total three-year DFS rate and the total three-year OS rate were 76.47% and 84.60% in all cases. Based on the Pearson Correlation Test, it was a significant correlation between the duration of IMRT time and three-year DFS (correlation=0.138, P = 0.017) and the number of concurrent cycles of chemotherapy with IMRT (correlation=0.375, P = 0.002). It was not a significant correlation between total time duration, MRI response, induction chemotherapy, age, sex, and the three-year DFS. There was a significant correlation between total time duration and three-year OS (correlation=0.263, P = 0.040) and the number of concurrent cycles of chemotherapy with IMRT and three-year OS (correlation=0.334, P = 0.007). It was not a significant correlation between the duration of IMRT time, MRI response, induction chemotherapy, age, sex, and the three-year OS. Conclusions: Our findings showed that IMRT with concurrent chemo-radiotherapy has the three-year DFS and OS, which were comparable with the other published results. We emphasize the number of concurrent cycles of chemotherapy with IMRT, which have an important role in both three-year DFS and OS. The duration of IMRT time has also an important role in the three-year DFS but not in the three-year OS. A longer follow-up for the patients to evaluate 10-year DFS and OS is recommended.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87532161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：